Intercalated regimen demonstrates first-line efficacy for advanced NSCLC
Administration of erlotinib in combination with chemotherapy is a viable first-line treatment strategy in patients with advanced non-small-cell lung cancer, results from FASTACT-2 suggest.
Source: MedWire News - Lung Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva